AMENDMENT NO. 1 TO DEPOSIT AGREEMENT BETWEEN ABLYNX NV, JPMORGAN CHASE BANK, N.A. AS DEPOSITARY AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS WORLDWIDE SECURITIES SERVICES jpmorgan.comDeposit Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
AMENDMENT NO. 1, dated as of , 2017 (the “Amendment”), to the Deposit Agreement dated as of September 5, 2014 (the “Deposit Agreement”), among Ablynx NV, incorporated under the laws of Belgium (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all holders from time to time of American depositary receipts (“ADRs”) issued thereunder.
EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and ABBVIE S.À.R.L. Dated as of September 20, 2013Exclusive License Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
This Exclusive License Agreement (the “Agreement”) is made and entered into effective as of September 20, 2013 (the “Effective Date”) by and between Ablynx NV, a company organized under the laws of Belgium, having its principal place of business at Technologiepark 21, B-9052 Ghent—Zwijnaarde, Belgium (“Ablynx”), and AbbVie S.à.r.l., a corporation organized under the laws of Luxembourg and having a principal place of business at 26 Boulevard Royal; L-2449 Luxembourg (“AbbVie”). Ablynx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SERVICE AGREEMENT REGARDING BUSINESS-SUPPORT CENTRE “BIO-ACCELERATOR”Service Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances)
On 10 October 2008, the Parties entered into a framework agreement and prepared an accompanying memorandum on commitments in order to make agreements on the conclusion of a service agreement with respect to the Services and Business-Support Centre Bio-Accelerator in 9052 Zwijnaarde, Technologiepark 21 (hereinafter jointly referred to as the “Framework Agreement”).
